Chromatrap Will be the Lead Sponsor at “Epigenetics in Drug Discovery”

Chromatrap®, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious “Epigenetics in Drug Discovery” conference to be held in Cambridge, UK from 26th-27th January 2016.

Viewed as a new frontier in drug discovery, rapid progress has been made in enhancing understanding of epigenetic mechanisms of both new and existing drugs. With the processes that control epigenomic function providing new opportunities, epigenetics targets are enabling the discovery of novel drugs. 

At the conference - Dr Amy Beynon will deliver a presentation highlighting the use of new Chromatrap solid state ChIP technology for assaying methylated and hydroxymethylated DNA marks in addition to Histone modifications and the use of Chromatrap kits for ChIP-sequencing. 

For further information on Chromatrap solid state ChIP technology please visit www.chromatrap.com or contact the customer services team on +44-1978-666222 /sales@chromatrap.com.

 

Chromatrap® is a business unit of Porvair Sciences, a wholly owned subsidiary of Porvair plc. To register to visit the Epigenetics conference please visit https://selectbiosciences.com/conferences/index.aspx?conf=EGDD2016

---------------------

Worldwide HQ 

ChromaTrap

A business unit of Porvair Sciences Ltd.

Clywedog Rd South
Wrexham Industrial Estate
Wales LL13 9XS
UK

Tel:     +44 1978 666222   
Email: sales@chromatrap.com
Web    www.chromatrap.com